About Cell-Easy
Data last updated:
Cell-Easy is a company based in Toulouse (France) founded in 2015 by Guillaume Costecalde and Benedikt Timmerman. Cell-Easy offers products and services including GMP Cell Banking, ATMP Manufacturing, Pharma Development, and MSC Transfer. Cell-Easy operates in a competitive market with competitors including Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Genflow Biosciences, among others.
- Headquarter Toulouse, France
- Founders Guillaume Costecalde, Benedikt Timmerman
- SectorsHealthcare
- EmailLocked
- PhoneLocked
- WebsiteLocked
- SocialLocked
- Legal Name Cell-Easy Sas
- Annual RevenueNot available
- Net ProfitNot available
- EBITDANot available
- Latest Funding RoundNot available
- InvestorsMerieux Equity Partners
& 2 more
- Employee CountNot available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cell-Easy
Cell-Easy offers a comprehensive portfolio of products and services, including GMP Cell Banking, ATMP Manufacturing, Pharma Development, and MSC Transfer.
Service for storing and managing cell banks under GMP standards.
Manufactures advanced therapy medicinal products for clinical use.
Supports optimization and scale-up of cell therapy processes.
Facilitates mesenchymal stem cell transfer and related services.
People of Cell-Easy
Unlock access to complete
Unlock access to complete
Funding Insights of Cell-Easy
Investors in Cell-Easy
Cell-Easy has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Merieux Equity Partners, M Capital and IRDI Capital Investissement.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pivate equity firm that focuses on investing in healthcare and nutrition companies | Locked | Locked | Locked | |
Investment solutions are provided by M Capital for various sectors. | Locked | Locked | Locked | |
Investment services are provided to startups, SMEs, and ETI in South-West France. | Locked | Locked | Locked |
Investor details for Cell-Easy
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cell-Easy
Investment portfolio details for Cell-Easy
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cell-Easy
Detailed financials for Cell-Easy
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cell-Easy Comparisons
Peer comparison for Cell-Easy
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cell-Easy
Cell-Easy operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and Genflow Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked | Cell and gene therapies for multiple disorders are developed. | |
| Locked | Locked | Locked | Software development services are provided for the biopharma sector. | |
| Locked | Locked | Locked | Services for cell therapy development and manufacturing are provided. | |
| Locked | Locked | Locked | Development and manufacturing services for cell-based therapies are provided. | |
| Locked | Locked | Locked | A biotechnology company focused on anti-aging therapeutics development. |
Detailed competitors of Cell-Easy
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cell-Easy
Complete news archive for Cell-Easy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cell-Easy
Cell-Easy was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Cell-Easy is headquartered in Toulouse, France. It is registered at Toulouse, Occitanie, France.
Cell-Easy was established in 2015 in Toulouse, France, within the biotechnology sector. Services centered on stem cell-based therapy for research applications are delivered. Allogeneic stem cells sourced from adipose tissue and prepared for injection are developed to support preclinical and clinical phases of drug development. Operations emphasize ready-to-use solutions for therapeutic research.
Cell-Easy's top competitors include Ori Biotech, MaSTherCell and Genflow Biosciences.
Cell-Easy offers GMP Cell Banking, ATMP Manufacturing, Pharma Development, and MSC Transfer.
Cell-Easy has 3 investors. Key investors include Merieux Equity Partners, M Capital, and IRDI Capital Investissement.